What the Fundus

We're back after a brief hiatus to talk about a paper published in Contact Lens and Anterior Eye about the incidence of positive corneal ulcer cultures.

Sorry, this is a few days late this week, but things have been a little crazy. Sara and I talk about a study discussing red light therapy to slow myopia progression. I also talk about my initial experience with Vuity. -- MM

Sara and I discuss the relatively quiet launch of Rayban Stories glasses. -- MM

Sara and I discuss the paper High-Fat Diet Induces Inflammation of Meibomian Gland. There are some problems with it, but the science is pretty great. -- MM

Dr. Toomey and I talk about a recently released drug called Tyrvaya from Oyster Point Pharmaceuticals. In this podcast we reference two articles. Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease: the ONSET-2 Phase 3, Randomized Trial and Randomized, Controlled, Double-Masked, Multicenter, Pilot Study Evaluating Safety and Efficacy of Intranasal Neurostimulation for Dry Eye Disease -- MM

This week Sara and I discuss the paper Lower Cognitive Function in Patients With Functionally and Structurally Severe Glaucoma: The LIGHT Study from the Journal of Glaucoma. -- MM

Today we cover a recent study that discusses treatment of central serous chorioretinopathy. Thanks for listening. If you have any suggestions for topics you want us to cover, please reach out to Michael on Twitter @mikeeyes. 

The link to the article regarding Parkinsons Disease and the eye can be found here.

This week, Sara and Michael talk about the newly approved drop to treat the symptoms of presbyopia called Vuity. You can get samples by visiting their website. 

(One correction: I referred to Dr. David Sinclair's excellent book Lifespan as "Ageless". I apologize for the the error -- MM)

Dr. Toomey discusses her experience with doing genetic testing on patients in her time at Bascom Palmer. Here's a link to the lab that does IRD testing that I incorrectly referred to as Invictus. It is Invitae. To learn more about treating IRD, head to Spark Therapeutics for more information. 

Welcome to the inaugural What the Fundus podcast. In this episode we talk about a new study involving Xiidra. For more information or for more eye-related information, check out our website. The study we talk about in this episode can be found here.